POS0110 ASSOCIATION OF miR-155 AND miR-34a EXPRESSION IN LUPUS NEPHRITIS RENAL TISSUE WITH DISEASE ONSET AND OUTCOMES

Background: Epigenetic factors such as non-coding RNA (miRNA) have been shown to be deregulated in Systemic Lupus Erythematosus (SLE). In mouse models, different miRNAs associated with lupus nephritis (LN), one of the most severe manifestations disease 1 . Objectives: To evaluate expression miR-155 and miR-34a renal tissues biomarkers organ involvement inflammatory tissue activity patients LN. Methods: Thirty-two SLE LN (age: 32.2 ± 9.2 years) active undergoing ultrasound-guided biopsy were enrolled between 2010 2019. The nephritic manifestation was present 13 (41%) at onset (early-LN SLE), while 19 (59%) showed a after (long-LN SLE, mean duration onset: 7.3 5.7 years). Twelve age-matched IgA nephropathy control group. Clinical, laboratory demographic data collected for each patient. Disease recorded using SLEDAI-2K activity, total fraction including items related involvement. MiR-155 carried out by extraction from paraffin-preserved biopsies evaluated, retrotrascription protocol, real-time PCR relative quantification considering ΔCt (Ct miRNA- Ct housekeeping gene) 2 Results: higher LN-SLE compared (ΔCt miR-155: 9.4 10.1 vs 21.9 3.6, p<0.01; miR-34a: 9.8 19.2 3.1, p=0.02). comparable histological classes. Furthermore, direct correlation observed (r = 0.91, p <0.001). Dividing based on onset, long-LN 6.1 8.7) 7.1 9.0) early-LN (miR-155: 13.4 10.6 0.08; 15.1 9.5 0.02) or (miR-155 p<0.01 p<0.01). Moreover, it an inverse C3 C4 complement components (r=-0.7.2; p=0.05 r=-0.86; p=0.01, respectively) 24h-UP (r=0,67; p=0.03). Considering early-LN, slightly significant who had relapsed 8.2 11.4 18.4 7.9 0.08), although no emerged time indices. Conclusion: may represent activation LN; particular, these miRNA p24h-UP could indicate possible role later onset. increased give indications recurrence suggesting closer monitoring patients. References: [1]Leiss H et al. Plosone 2017. [2]Alivernini S Nat Commun 2018. Disclosure Interests: None declared